Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma

Balazs Hegedus, Debasish Banerjee, Tu Hsueh Yeh, Stefan Rothermich, Arie Perry, Joshua B. Rubin, Joel R. Garbow, David H. Gutmann

研究成果: 雜誌貢獻文章同行評審

110 引文 斯高帕斯(Scopus)

摘要

Mouse models of human cancers afford unique opportunities to evaluate novel therapies in preclinical trials. For this purpose, we analyzed three genetically engineered mouse (GEM) models of low-grade glioma resulting from either inactivation of the neurofibromatosis-1 (Nf1) tumor suppressor gene or constitutive activation of KRas in glial cells. Based on tumor proliferation, location, and penetrance, we selected one of these Nf1 GEM models for preclinical drug evaluation. After detection of an optic glioma by manganese-enhanced magnetic resonance imaging, we randomized mice to either treatment or control groups. We first validated the Nf1 optic glioma model using conventional single-agent chemotherapy (temozolomide) currently used for children with low-grade glioma and showed that treatment resulted in decreased proliferation and increased apoptosis of tumor cells in vivo as well as reduced tumor volume. Because neurofibromin negatively regulates mammalian target of rapamycin (mTOR) signaling, we showed that pharmacologic mTOR inhibition in vivo led to decreased tumor cell proliferation in a dose-dependent fashion associated with a decrease in tumor volume. Interestingly, no additive effect of combined rapamycin and temozolomide treatment was observed. Lastly, to determine the effect of these therapies on the normal brain, we showed that treatments that affect tumor cell proliferation or apoptosis did not have a significant effect on the proliferation of progenitor cells within brain germinal zones. Collectively, these findings suggest that this Nf1 optic glioma model may be a potential preclinical benchmark for identifying novel therapies that have a high likelihood of success in human clinical trials.
原文英語
頁(從 - 到)1520-1528
頁數9
期刊Cancer Research
68
發行號5
DOIs
出版狀態已發佈 - 三月 1 2008
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma」主題。共同形成了獨特的指紋。

引用此